Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on X:
“CtDNA is here and SABCS25 confirmed it.
Sure we don’t know yet what to do with positive ctDNA and studies are needed. But patients want a better understanding of risk than we currently provide.”
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared this post, adding:
“NSABP B-59/Gepardouze ctDNA substudy (Exact sciences assay) n=212
- BL 96% MRD positive
- Post NAT: 9%
- Post surgery: 6%
30-fold increase risk of distant recurrence if MRD positive post surgery.
95% of pts MRD negative post surgery remain free of disease at 3 years.”
More posts featuring Sarah Sammons.